Drug General Information (ID: DDID2CMHY0)
  Drug Name Mesoridazine Drug Info Halofantrine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antipsychotic Agents Antimalarial Agents
  Structure

 Mechanism of Mesoridazine-Halofantrine Interaction (Severity Level: Major)
     Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Mesoridazine Halofantrine
      Mechanism Prolong QT interval Prolong QT interval
      Key Mechanism Factor 1
Factor Name QT interval
Factor Description Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
      Mechanism Description
  • Increased risk of prolong QT interval by the combination of Mesoridazine and Halofantrine 

Recommended Action
      Management Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.

References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Product Information. Halfan (halofantrine). GlaxoSmithKline, Philadelphia, PA.
3 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.